Monopar Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Monopar Therapeutics generated cash of -$7,858,293, which is less than the previous year. Cash used in financing activities reached the amount of $2,027,227 last year. Net change in cash is therefore -$920,114.
Cash Flow
| 2015 | -636.32K | 0 | 3.44M |
|---|---|---|---|
| 2016 | -1.19M | 0 | 1.26M |
| 2017 | -2.62M | 0 | 9.53M |
| 2018 | -2.88M | 0 | 0 |
| 2019 | -3.01M | 0 | 9.34M |
| 2020 | -4.66M | 0 | 8.18M |
| 2021 | -7.31M | 0 | 10.87M |
| 2022 | -7.22M | -4.91M | 32.87K |
| 2023 | -7.85M | 4.92M | 2.02M |
MNPR Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 8.18M | 20.30M | 16.73M | 13.21M | 6.89M | 9.78M | 2.87M | 2.80M | -800.00K |
Operating activities | |||||||||
Net income | -8.40M | -10.51M | -9.10M | -6.30M | -4.22M | -3.22M | -16.55M | -1.18M | -687.31K |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Stock-based compensation expense | 1.89M | 1.64M | 1.46M | 1.32M | 1.01M | 0 | 305.20K | 0 | 0 |
| Deferred income tax benefit | 1.89M | 1.64M | 1.46M | 1.32M | 1.01M | 0 | 305.20K | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -1.33M | 1.47M | 403.96K | 447.59K | 243.53K | 87.68K | 247.35K | -9.33K | 73.84K |
Cash generated by operating activities | -7.85M | -7.22M | -7.31M | -4.66M | -3.01M | -2.88M | -2.62M | -1.19M | -636.32K |
Investing activities | |||||||||
Purchases Of Investments | -7.88M | -4.91M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 4.92M | -4.91M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Financing activities | |||||||||
Common Stock Issued | 2.07M | 109.33K | 10.92M | 8.17M | 10.22M | 0 | 4.70M | 0 | 3.44M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -63 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -122.4K | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 2.02M | 32.87K | 10.87M | 8.18M | 9.34M | 0 | 9.53M | 1.26M | 3.44M |
Net Change In Cash | -920.11K | -12.11M | 3.56M | 3.52M | 6.32M | -2.88M | 6.90M | 67.86K | 2.80M |
Cash at end of period | 7.26M | 8.18M | 20.30M | 16.73M | 13.21M | 6.89M | 9.78M | 2.87M | 2.00M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |